An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis
Status:
Completed
Trial end date:
2021-06-29
Target enrollment:
Participant gender:
Summary
This is a study of itacitinib (INCB039110) in patients with myelofibrosis. This study will
evaluate safety and efficacy parameters of itacitinib (INCB039110).